Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has maintained an Outperform rating on Corbus Pharmaceuticals (NASDAQ:CRBP) and raised the price target from $58 to $60.
May 08, 2024 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer maintains an Outperform rating on Corbus Pharmaceuticals and raises the price target from $58 to $60.
The increase in price target by a reputable analyst like Jeff Jones from Oppenheimer suggests a strong confidence in Corbus Pharmaceuticals' future performance. This endorsement is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100